{"generic":"Palifermin","drugs":["Kepivance","Palifermin"],"mono":{"0":{"id":"928350-s-0","title":"Generic Names","mono":"Palifermin"},"1":{"id":"928350-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928350-s-1-4","title":"Adult Dosing","mono":"<b>Mucositis following chemotherapy, In patients requiring stem cell transplant; Prophylaxis:<\/b> 60 mcg\/kg\/day IV bolus for 3 consecutive days before (the third dose should be within 24 to 48 hours of starting myelotoxic therapy) and 3 consecutive days after myelotoxic therapy (first of these doses should be administered after, but on the same day of hematopoietic stem cell infusion and more than 4 days after the final dose of the initial dosing sequence); a total of 6 doses is given "},"1":{"id":"928350-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness in pediatric patients have not been established "},"3":{"id":"928350-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Mucositis following chemotherapy, In patients requiring stem cell transplant; Prophylaxis<br\/><b>Non-FDA Labeled Indications<\/b><br\/>Mucositis following chemotherapy, In patients with solid tumor malignancies; Prophylaxis<br\/>"}}},"3":{"id":"928350-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928350-s-3-9","title":"Contraindications","mono":"Specific contraindications have not been determined <br\/>"},{"id":"928350-s-3-10","title":"Precautions","mono":"<ul><li>Other:<\/li><li>-- Administration may stimulate non-hematopoietic tumor growth<\/li><li>Concomitant Use:<\/li><li>-- Use not recommended with melphalan 200 mg\/m(2) as a conditioning regimen<\/li><li>-- Do not administer within 24 hours before, during, or within 24 hours after myelotoxic chemotherapy due to risk of increased severity and duration of oral mucositis<\/li><\/ul>"},{"id":"928350-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B3 (AUS)<\/li><\/ul>"},{"id":"928350-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928350-s-4","title":"Drug Interactions","sub":{"2":{"id":"928350-s-4-15","title":"Moderate","mono":"<ul><li>Ardeparin (probable)<\/li><li>Certoparin (probable)<\/li><li>Dalteparin (probable)<\/li><li>Enoxaparin (probable)<\/li><li>Heparin (probable)<\/li><li>Nadroparin (probable)<\/li><li>Parnaparin (probable)<\/li><li>Reviparin (probable)<\/li><li>Tinzaparin (probable)<\/li><\/ul>"}}},"5":{"id":"928350-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Edema (28%)<\/li><li><b>Dermatologic:<\/b>Erythema (32%), Pruritus (35%), Rash (62%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain, Enlargement of tongue, Increased serum lipase level (28%), Loss of appetite, Serum amylase raised (overall, 62%; grade 3 and 4, 38%), Taste sense altered (hematologic malignancy, 16%;), Tongue discoloration, Vomiting<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (10%)<\/li><li><b>Neurologic:<\/b>Dysesthesia (12%)<\/li><li><b>Other:<\/b>Fever (39%), Pain (16%)<\/li><\/ul><b>Serious<\/b><br\/><b>Gastrointestinal:<\/b>High lipase level in serum (grade 3 and 4 elevation, 11%)<br\/>"},"6":{"id":"928350-s-6","title":"Drug Name Info","sub":{"0":{"id":"928350-s-6-17","title":"US Trade Names","mono":"Kepivance<br\/>"},"2":{"id":"928350-s-6-19","title":"Class","mono":"<ul><li>Keratinocyte Growth Factor<\/li><li>Protectant, Dental<\/li><\/ul>"},"3":{"id":"928350-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928350-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928350-s-7","title":"Mechanism Of Action","mono":"Palifermin, a human keratinocyte growth factor (KGF) produced by recombinant DNA technology, is an endogenous protein in the fibroblast growth factor (FGF) family. Palifermin binds to the KGF receptor, causing proliferation, differentiation, and migration of epithelial cells.<br\/>"},"8":{"id":"928350-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"928350-s-8-24","title":"Distribution","mono":"Vd: (cancer patients), 2-fold higher <br\/>"},"4":{"id":"928350-s-8-27","title":"Elimination Half Life","mono":"4.5 h (3.3 h to 5.7 h) <br\/>"}}},"9":{"id":"928350-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>add sterile water for injection to vial for a final concentration of 5 mg\/mL, gently swirl, do not shake or vigorously agitate vial; dissolution can take up to 3 minutes<\/li><li>(bolus) give reconstituted solution immediately or store protected from light (in carton) for a maximum of 1 hour at room temperature or 24 hours if refrigerated<\/li><li>do not filter reconstituted solution during preparation or administration<\/li><li>if heparin is used to maintain the IV line, flush with saline prior to and after the dose to prevent binding to heparin<\/li><\/ul>"},"10":{"id":"928350-s-10","title":"Monitoring","mono":"symptomatic improvement, decreased mouth and throat soreness<br\/>"},"11":{"id":"928350-s-11","title":"How Supplied","mono":"<b>Kepivance<\/b><br\/>Intravenous Powder for Solution: 6.25 MG<br\/>"},"13":{"id":"928350-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause thickening or discoloration of the tongue, altered taste, arthralgia, dysesthesia, pain, or fever.<\/li><li>Instruct patient to report signs\/symptoms of cutaneous toxicity (pruritus, rash, edema, erythema).<\/li><\/ul>"}}}